The Board of Directors of Genesis IBRC India Limited ('Company') in their meeting held today, i.e., Wednesday, January 28, 2026, have inter alia, considered, recommended, and approved the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.3 pts more than Nifty Microcap 250 and 5.5 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board of Genesis IBRC India Limited approved issuing up to 4.02 crore equity shares at Rs 10 each (face value, no premium) on a preferential basis to 11 investors, including 2 promoters and 9 non-promoters, raising Rs 40.25 crores. Combined with a prior tranche, total preferential equity reaches 5.32 crore shares worth Rs 53.25 crores. The board also cleared raising authorised share capital from Rs 13 crores to Rs 60 crores to accommodate the issue. Separately, the company proposes to alter its main object clause to enter the FMCG, commodities and minerals businesses, replacing its existing objects, citing the new management's expertise in these sectors. All key resolutions including the share issue, capital hike and object change will go to shareholders via postal ballot, with January 30, 2026 set as the cut-off date and February 3, 2026 as the relevant date for pricing the preferential issue.
Existing shareholders will see significant equity dilution since the issue is at par (no premium) and goes to a select group of investors. The shift into FMCG and commodities represents a major strategic pivot, and shareholder approval will be needed before the new shares and business direction take effect.